Search Results

FDA

FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

August 22, 2024

·

5 min read

FDA

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2

August 22, 2024

·

6 min read

Press Releases

Moderna R&D Day Highlights Progress and Strategic Priorities

September 12, 2024

·

22 min read

Moderna, Inc.

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates.

FDA

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)

Moderna, Inc. announced that the U.S. Food and Drug Administration has approved mRESVIA, an mRNA respiratory syncytial virus vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.

May 31, 2024

·

6 min read

FDA

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R) - May 31, 2024

Moderna, Inc. announced that the U.S. Food and Drug Administration has approved mRESVIA, an mRNA respiratory syncytial virus vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.

May 31, 2024

·

6 min read

Press Releases

FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

September 2, 2024

·

3 min read

FDA

FDA Roundup: May 31, 2024

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

May 31, 2024

·

6 min read

Job Trends

FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

Today, the U.S. Food and Drug Administration took action approving and authorizing for emergency use updated COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death.

September 11, 2023

·

6 min read

Business

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

Harbour BioMed (the “Company”, HKEX: 02142) today announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX, Inc. (NASDAQ: MRNA), a global biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines.

November 10, 2022

·

3 min read